01-04-2010
IGM
IGM Resins acquires the Photomer® UV Acrylates business from Cognis
PRESS RELEASE
Waalwijk, April 1, 2010
IGM Resins, Waalwijk, The Netherlands has signed an agreement with Cognis to purchase the Photomer® UV Acrylates business. The purchase is expected to be formally completed by June 2010.
The Cognis range of epoxy, polyester and urethane acrylates together with a broad range of reactive diluents marketed under the trade name Photomer® provide unique benefits in UV/EB curing applications. A wide range of these acrylates are available as solvent-free versions (F grades) meeting stringent demands in VOC free applications.
Under the terms of the transaction IGM Resins acquires the Photomer® trademarks, intellectual property, inventory and the
John Huiberts, CEO of IGM Resins commented “this acquisition of the Photomer® UV acrylates business compliments and strengthens IGM Resins position as a fully integrated leading supplier of raw materials to the radiation curing industry globally and is a significant boost for our business”.
“The Photomer® business has a strong market position globally and is a highly respected brand and IGM Resins aim is to further develop and strengthen that position. With UV acrylates manufacturing in North America, Europe and
the demands of radiation curing ink, coatings and adhesives manufactures globally”.
Executive Vice President Cognis Functional Products Paul Allen commented “We firmly believe that we have found a growing and entrepreneurial player in the global UV acrylates business that is in the position to develop the business successfully and enabling a more comprehensive product offering for the customers. We will work closely together with IGM
Resins to ensure a smooth transition of the business.”
About IGM Resins
Founded in 1999 IGM Resins is a global specialty chemicals company focusing on UV radiation curing markets. Today IGM Resins has offices and production facilities in several European countries, the
business. IGM Resins’ strategy is to expand its portfolio, services, production, technical support and product development in support of UV radiation curing markets globally.
About Cognis
Cognis is a worldwide supplier of innovative specialty chemicals and nutritional ingredients, with a particular focus on the areas of wellness and sustainability. The company employs about 5,600 people, and it operates production sites and service centers in 30 countries.
Cognis has dedicated its activities to a high level of sustainability and provides value adding solutions and products based on renewable raw materials. The company serves the food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries.
Another main focus is on products for a number of other industries, such as coatings and inks, lubricants, as well as agriculture and mining.
Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and SV Life Sciences. In 2009, Cognis recorded sales of about 2.6 billion euros and an Adjusted EBITDA (operating result) of 364 million euros.
Contact
Stephanie van den Dungen, Management coordination
IGM
Phone + 31 416 316 657
Email S.vandenDungen@igmresins.com
NEW PUBLIC CONSULTATION ON 15 POTENTIAL SUBSTANCES OF VERY HIGH CONCERN
02-10-2009
The European Chemicals Agency (ECHA) has published on its website proposals to
identify chemicals as Substances of Very High Concern (SVHC). Interested parties are
welcome to comment on these 15 substances within the next 45 days. The comments
will be taken into account when deciding whether the substances will be added to the
Candidate List from which substances are selected for authorisation.
Anyone can comment by 15 October 2009, on the 15 proposals to identify chemicals asSubstances of Very High Concern. These substances were proposed by EU/EEA Member States and by the European Commission. Comments should particularly focus on the hazardous properties that qualify the chemicals as SVHCs. In addition, parties can provide comments and further information on the uses, exposures and availability of safer alternative substances or techniques, although these aspects will mainly be considered at the next stage of the process which includes a new round of public consultation. Comments received during the consultation period will be submitted to ECHA’s Member State Committee when it is deciding whether it agrees with the proposed identification of the substances as SVHC. If the Committee unanimously agrees to the proposals, ECHA will place the substances on the so-called Candidate List, which already contains 15 substances. Substances appearing on this list may eventually be included in the list of substances subject
to authorisation (the Authorisation List). In this case, after a transition period, they can onlybe used if a specific authorisation is granted. Information requirements for suppliers of substances, preparations and articles containing these substances will also follow from the inclusion of the substances in the Candidate List. Nine out of the 15 substances are proposed to be identified as SVHCs because of their carcinogenic, mutagenic and/or reprotoxic (CMR) properties, having thus potentially serious effects on human health. Five substances are proposed to be identified as persistent, bioaccumulative and toxic and as very persistent and very bioaccumulative (PBT), having potentially serious negative effects on the environment. One substance is proposed because it is considered both as CMR and PBT.
DSM Special Products sale to Arsenal Capital Partners will not be completed
06-02-2009
Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that the previously announced sale of DSM Special Products BV to Arsenal Capital Partners (United States) will not be completed.
The transaction was originally announced on 3 March 2008. In August 2008, the European Commission announced an in-depth investigation into the transaction. Last month, the European Commission approved the sale, but the conditions the Commission demanded have led to the conclusion that the intended sale is no longer feasible. DSM regrets that the transaction cannot be completed and will continue the divestment process for DSM Special Products, as part of its Vision 2010 strategy.
DSM Special Products is the producer of Purox®, an ingredient used in food as well as in a range of industrial applications. It also produces an ingredient for VevoVitall®, a product for the animal health market that will remain with DSM Nutritional Products. DSM Special Products employs around 130 people in Rotterdam and Sittard (Netherlands), and has an annual turnover of approximately EUR 100 million. DSM – the Life Sciences and Materials Sciences Company Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM’s products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. DSM has annual sales of almost EUR 8.8 billion and employs some 23,000 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com.
Public consultation on inclusion of substances in the authorisation list
29-01-2009
ECHA launched today a public consultation on the first draft recommendation of substances to be included in the list of substances subject to authorisation (Annex XIV or Authorisation List). Interested parties can submit comments by using the relevant web forms on the ECHA website until 14 April 2009.
The public consultation on the draft recommendation is part of the process to include substances in Annex XIV of REACH (Authorisation List). For an overview of the process, see Attachment 1 of this document.
PUBLIC CONSULTATION
Interested parties can comment both on:
• ECHA’s draft recommendation on seven substances (see below) and its reasoning behind their inclusion in Annex XIV and
• ECHA’s justification for prioritising these substances. Interested parties are invited to comment in particular on uses which should be exempted
from the authorisation requirements. The web forms on the ECHA website must be used forcommenting. The closing date for comments is 14 April 2009.
ECHA’S DRAFT RECOMMENDATION
Based on an assessment of the available information, ECHA recommends prioritising seven substances out of the 15 substances that are on the Candidate List (published 28 October 2008). The prioritised substances are:
• 5-tert-butyl-2,4,6-trinitro-m-xylene (musk xylene)
• Alkanes,C10-13,chloro (short chain chlorinated paraffins; SCCPs)
• Hexabromocyclododecane (HBCDD) and all major diastereoisomers identified
• 4,4’-Diamino diphenyl methane (MDA)
• Bis (2-ethylhexyl) phthalate (DEHP)
• Benzyl butyl phthalate (BBP)
• Dibutyl phthalate (DBP)
Addition of predispersed pigments to the CDT product range
28-01-2009
CDT is very happy to announce the addition of a range of new products to the existing product range. CDT predispersed pigments are flushed organic pigments especially developed for the masterbatch industry for making high performance colour masterbatches.
CDT predispersed pigments are manufactured during pigment synthesis by the flushing process technology to ensure maximum pigment dispersion. They are ‘pre-wetted’ and pre-dispersed in an polyolefinic medium to give maximum colour yield in the production of polyethylene and polypropylene based masterbatches. They are available as ‘free flowing and non dusting’ powders. The combination of waxes added during the flushing process provides a high affinity to polyethylene and polypropylene and thus pave for excellent pigment dispersion in these polymers. CDT predispersed pigments are available in a variety of colours suited for your application.
European Commission clears acquisition of DSM Special Products
13-01-2009
The European Commission has approved under the EU Merger Regulation the proposed acquisition of chemical company DSM Special Products of the Netherlands by Arsenal Capital Partners.
Mergers: Commission clears proposed acquisition of DSM Special Products by Arsenal Capital Partners, subject to conditions
The European Commission has approved under the EU Merger Regulation the proposed acquisition of chemical company DSM Special Products (DSP)of The Netherlands by Arsenal Capital Partners (Arsenal), a US private equity firm. Arsenal owns Velsicol, a chemical company active in the EEA through its Estonian plant. DSP is a chemical company with a single production plant, in Rotterdam. Both parties produce benzoic acid, a raw material used in the production of a variety of goods, including as an antimicrobial preservative in food and drinks, in plasticisers, pharmaceutical goods and pet food. In August 2008, the Commission opened an in-depth investigation (see IP/08/1249) because of competition concerns. Arsenal made the commitmentto divest the whole of its liquid and solid benzoic acid production, as well as sodium benzoate production in the European Economic Area (EEA). In the light of these commitments, the Commission concluded that the proposed transaction would not significantly impede effective competition in the EEA or any substantial part of it.
Competition Commissioner Neelie Kroes said: "Without strong remedies, the planned acquisition would have led to a quasi-monopoly and to a serious risk that consumers would be worse off. In the light of the divestments offered, I am now satisfied that effective competition will be ensured." The Commission found that the proposed transaction would have raised serious competition concerns in the EEA market for solid benzoic acid, where the merged entity would have run the only two production plants in the EEA. The Commission also found that imports of benzoic acid into the EEA are very low and would not be capable of constraining the merged entity. To address the Commission's concerns, Arsenal offered to divest the Velsicol production plant in Estonia and therefore its entire solid and liquid benzoic acid production. The proposed divestment also includes the production of sodium benzoate, a product derived from benzoic acid and used primarily as a preservative
in food and soft drinks, to ensure the full viability of the divested business. The buyer of the divested business will therefore be in a position to compete in the market for solid benzoic acid and become a credible alternative supplier. In view of this commitment, the Commission concluded that the transaction would no longer raise serious competition concerns.
CD&T and REACH
18-09-2008
CD&T is happy to anounce that all products will be (pre-)registered under the REACH directive.
We are glad to inform you that all products in our product range, in case of monomers, will be pre-registered. When substances are polymers, Chemical Distribution & Trade has confirmation that our suppliers will (pre-)register the substances and additives, which are found in quantities higher than 2% in these polymers.
These decisions by our suppliers ensure the continued supply of products to you, our customer. We hope that, with this information, we have informed you sufficient and hope that you will remain in business with Chemical Distribution & Trade.
Additional questions and comments can be directed to info@cdteurope.com
New website CD&T effective from the beginning of September 2008
09-09-2008
To provide our customers with better service we have chanced the CD&T website. Please have a look at our new and updated product range.
